sign in sign up
<<
Home , Terbutaline

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

1. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, Lomas DA, Wouters E, Bakke P, Rennard S et al: Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. The European respiratory journal 2013, 42(3):636-646.

2. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC et al: Azithromycin for prevention of exacerbations of COPD. The New England journal of medicine 2011, 365(8):689-698.

3. ANI Pharmaceuticals Inc: Terbutaline Sulfate. In: US Product Monograph. Baudette, MN; 2018.

4. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of internal medicine 1987, 106(2):196-204.

5. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM: Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 2006(3):CD001104.

6. AstraZeneca Canada Inc: Pulmicort Nebuamp (). In: CA Product Monograph. Mississauga, ON; 2013.

7. AstraZeneca Canada Inc: Symbicort Turbuhaler (budesonide / fumarate dihydrate). In: CA Product Monograph. Mississauga, ON; 2016.

8. AstraZeneca Canada Inc: Duaklir Genuair (/formoterol fumarate dihydrate). In: CA Product Monograph. Mississauga, ON; 2017.

9. Astrazeneca Canada Inc: Daxas (). In: CA Product Monograph. Mississauga, ON; 2017.

10. AstraZeneca Canada Inc: Pulmicort Turbuhaler (budesonide). In: CA Product Monograph. Mississauga, ON; 2017.

11. AstraZeneca Canada Inc: Alvesco (). In: CA Product Monograph. Mississauga, ON; 2017.

12. AstraZeneca Canada Inc: Tudorza Genuair (aclidinium bromide). In: CA Product Monograph. Mississauga, ON; 2017.

13. Astrazeneca Canada Inc: Bevespi Aerosphere (glycopyrronium / formoterol fumarate dihydrate). In: CA Product Monograph. Mississauga, ON; 2018.

14. AstraZeneca Canada Inc: Oxeze Turbuhaler (formoterol fumarate dihydrate). In: CA Product Monograph. Mississauga, ON; 2018.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

15. AstraZeneca Canada Inc: Bricanyl Turbuhaler (terbutaline sulfate). In: CA Product Monograph. Mississauga, ON; 2018.

16. AstraZeneca Pharmaceuticals LP: Symbicort (budesonide / formoterol fumarate dihydrate). In: US Product Monograph. Wilmington, DE; 2017.

17. AstraZeneca Pharmaceuticals LP: Tudorza Pressair (aclidinium bromide). In: US Product Monograph. Wilmington, DE; 2018.

18. AstraZeneca Pharmaceuticals LP: Daliresp (roflumilast). In: US Product Monograph. Wilmington, DE; 2018.

19. Aubier M: Pharmacotherapy of respiratory muscles. Clinics in chest medicine 1988, 9(2):311- 324.

20. Barnes PJ: New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013, 12(7):543-559.

21. Barr RG, Bourbeau J, Camargo CA, Ram FS: Inhaled tiotropium for stable chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 2005(2):CD002876.

22. Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S: beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or . The Journal of allergy and clinical immunology 2009, 124(6):1188-1194.e1183.

23. BC Renal Agency: Common oral antimicrobial therapy dosage adjustments for renal function. In.; 2018.

24. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, Dorinsky PM: Salmeterol response is not affected by beta2- genotype in subjects with persistent . The Journal of allergy and clinical immunology 2006, 118(4):809-816.

25. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M: Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet (London, England) 2007, 370(9605):2118-2125.

26. Bleecker ER, Meyers DA, Bailey WC, Sims AM, Bujac SR, Goldman M, Martin UJ: ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest 2012, 142(2):320-328.

27. Blondel-Hill E, Fryters S: Bugs & Drugs. In. Calgary: Alberta Health Services; 2012.

28. Boardman C, Chachi L, Gavrila A, Keenan CR, Perry MM, Xia YC, Meurs H, Sharma P: Mechanisms of action and insensitivity in airways disease. Pulmonary pharmacology & therapeutics 2014, 29(2):129-143.

29. Boehringer Ingelheim (Canada) Ltd: Combivent UDV (ipratropium / ). In: CA Product Monograph. Burlington, ON; 2015.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

30. Boehringer Ingelheim (Canada) Ltd: Atrovent HFA (ipratropium). In: CA Product Monograph. Burlington, ON; 2016.

31. Boehringer Ingelheim (Canada) Ltd: Combivent Respimat (ipratropium and salbutamol). In: CA Product Monograph. Burlington, ON; 2016.

32. Boehringer Ingelheim (Canada) Ltd: Striverdi Respimat (). In: CA Product Monograph. Burlington, ON; 2016.

33. Boehringer Ingelheim (Canada) Ltd: Spiriva Respimat (tiotropium). In: CA Product Monograph. Burlington, ON; 2016.

34. Boehringer Ingelheim (Canada) Ltd: Inspiolto Respimat (tiotropium / olodaterol). In: CA Product Monograph. Burlington, ON; 2017.

35. Boehringer Ingelheim (Canada) Ltd: Spiriva (tiotropium). In: CA Product Monograph. Burlington, ON; 2017.

36. Boehringer Ingelheim (Canada) Ltd: Spiriva Respimat (tiotropium). In: CA Product Monograph. Burlington, ON; 2019.

37. Boehringer Ingelheim Pharmaceuticals Inc: Spiriva Handihaler (tiotropium). In: US Product Monograph. Ridgefield, CT; 2018.

38. Boehringer Ingelheim Pharmaceuticals Inc: Stiolto Respimat (tiotropium / olodaterol). In: US Product Monograph. Ridgefield, CT; 2018.

39. Boehringer Ingelheim Pharmaceuticals Inc: Striverdi Respimat (olodaterol). In: US Product Monograph. Ridgefield, CT; 2018.

40. Boehringer Ingelheim Pharmaceuticals Inc: Spiriva Respimat (tiotropium). In: US Product Monograph. Ridgefield, CT; 2018.

41. Boehringer Ingelheim Pharmaceuticals Inc: Spiriva Respimat (tiotropium). In: US Product Monograph. Ridgefield, CT 2019.

42. Bonini M, Permaul P, Kulkarni T, Kazani S, Segal A, Sorkness CA, Wechsler ME, Israel E: Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. American journal of respiratory and critical care medicine 2013, 188(12):1407-1412.

43. British Columbia Guidelines and Protocols Advisory Committee: Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and management. In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2017.

44. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (London, England) 2009, 374(9691):685-694.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

45. Canadian Pharmacists Association: Corticosteroids: inhaled [CPhA monograph]. In: RxTx. Ottawa, ON; 2016.

46. Canadian Pharmacists Association: Erythromycin [CPhA monograph]. In: RxTx. Ottawa, ON; 2018.

47. Chong J, Leung B, Poole P: Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 2013(11):CD002309.

48. Cosio BG, Shafiek H, Iglesias A, Yanez A, Cordova R, Palou A, Rodriguez-Roisin R, Peces-Barba G, Pascual S, Gea J et al: Oral Low-dose on Top of Inhaled -Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest 2016, 150(1):123-130.

49. Covis Pharma: Alvesco (ciclesonide). In: US Product Monograph. Zug, Switzerland; 2018.

50. Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F et al: Pneumonia risk with inhaled fluticasone furoate and compared with vilanterol alone in patients with COPD. Annals of the American Thoracic Society 2015, 12(1):27-34.

51. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, Curren K, Balter MS, Bhutani M, Camp PG et al: Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015, 147(4):894-942.

52. Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P et al: The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. The Canadian journal of cardiology 2015, 31(5):549-568.

53. Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D et al: Once-daily versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. The Lancet Respiratory medicine 2013, 1(7):524-533.

54. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S: Dose adjustment in patients with liver disease. Drug safety 2005, 28(6):529-545.

55. Dijkstra A, Koppelman GH, Vonk JM, Bruinenberg M, Schouten JP, Postma DS: Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. The Journal of allergy and clinical immunology 2008, 121(6):1510-1513.

56. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting : two randomised clinical trials. Lancet (London, England) 2009, 374(9691):695-703.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

57. Finkelstein Y, Bournissen FG, Hutson JR, Shannon M: Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis. J Asthma 2009, 46(9):900-905.

58. Francis RS, Spicer CC: Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations and their cost. British medical journal 1960, 1(5169):297-303.

59. Francis RS, May JR, Spicer CC: Chemotherapy of bronchitis. Influence of penicillin and tetracycline administered daily, or intermittently for exacerbations. A report to the Research Committee of the British Tuberculosis Association by its Bronchitis Subcommittee. BMJ 1961, 2(5258):979-985.

60. Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, Bartoloni A, Losito AR, Corcione S, Bartoletti M et al: Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case- control-control study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2015, 21(12):1106 e1101-1108.

61. Giubergia V, Gravina L, Castanos C, Chertkoff L: Influence of beta(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2013, 110(3):156-160.

62. GlaxoSmitheKline: Breo Ellipta (fluticasone furoate / vilanterol). In: US Product Monograph. Research Triange Park, NC; 2019.

63. GlaxoSmithKline Inc: Serevent Diskhaler/Diskus (salmeterol). In: CA Product Monograph. Mississauga, ON; 2014.

64. GlaxoSmithKline Inc: Flovent HFA and Diskus (). In: CA Product Monograph. Mississauga, ON; 2016.

65. GlaxoSmithKline Inc: Incruse Ellipta (umeclidinium). In: CA Product Monograph. Mississauga, ON; 2017.

66. GlaxoSmithKline Inc: Anoro Ellipta (umeclidinium / vilanterol). In: CA Product Monograph. Mississauga, ON; 2017.

67. GlaxoSmithKline Inc: Ventolin Diskus (salbutamol sulfate DPI) In: CA Product Monograph. Mississauga, ON; 2017.

68. GlaxoSmithKline Inc: Ventolin Nebules and Respirator (salbutamol sulfate ). In: CA Product Monograph. Mississauga, ON; 2017.

69. GlaxoSmithKline Inc: Arnuity Ellipta (fluticasone furoate DPI). In: CA Product Monograph. Mississauga, ON; 2017.

70. GlaxoSmithKline Inc: Ventolin HFA (salbutamol sulfate). In: CA Product Monograph. Mississauga, ON; 2017.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

71. GlaxoSmithKline Inc: Advair Diskus (fluticasone propionate / salmeterol). In: CA Product Monograph. Mississauga, ON; 2018.

72. GlaxoSmithKline Inc: Flovent HFA and Diskus (fluticasone propionate). In: CA Product Monograph. Mississauga, ON; 2018.

73. GlaxoSmithKline Inc: Breo Ellipta (fluticasone furoate / vilanterol). In: CA Product Monograph. Mississauga, ON; 2019.

74. GlaxoSmithKline LLC: Incruse Ellipta (umeclidinium). In: US Product Monograph. Research Triangle Park, NC; 2017.

75. GlaxoSmithKline LLC: Anoro Ellipta ( / vilanterol trifenantate). In: US Product Monograph. Research Triangle Park, NC; 2017.

76. GlaxoSmithKline LLC: Advair Diskus (fluticasone propionate / salmeterol). In: US Product Monograph. Research Triangle Park, NC; 2017.

77. GlaxoSmithKline LLC: Ventolin HFA (albuterol sulfate). In: US Product Monograph. Reasearch Triangle Park, NC; 2018.

78. GlaxoSmithKline LLC: Arnuity Ellipta (fluticasone furoate). In: US Product Monograph. Research Triangle Park, NC; 2018.

79. GlaxoSmithKline LLC: Flovent HFA (fluticasone propionate). In: US Product Monograph. Research Triangle Park, NC; 2019.

80. Global Initiative for Chronic : Pocket guide to COPD diagnosis, management, and prevention. A guide for health care professionals. In.; 2017.

81. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (2018 Report). In.; 2018.

82. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC et al: Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. American journal of respiratory and critical care medicine 2014, 189(12):1503-1508.

83. Herath SC, Poole P: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). The Cochrane database of systematic reviews 2013(11):CD009764.

84. Hizawa N, Makita H, Nasuhara Y, Betsuyaku T, Itoh Y, Nagai K, Hasegawa M, Nishimura M: Beta2-adrenergic receptor genetic polymorphisms and short-term responses in patients with COPD. Chest 2007, 132(5):1485-1492.

85. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J et al: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (London, England) 2004, 364(9444):1505-1512.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

86. Johnston RN, McNeill RS, Smith DH, Dempster MB, Nairn JR, Purvis MS, Watson JM, Ward FG: Five-year winter chemoprophylaxis for chronic bronchitis. BMJ 1969, 4(5678):265-269.

87. Karner C, Cates CJ: Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 2012(4):CD008989.

88. Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, Lee JH, Kim EK, Lee JH, Lee SM et al: Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008, 186(6):381-386.

89. Kim WJ, Sheen SS, Kim TH, Huh JW, Lee JH, Kim EK, Lee JH, Lee SM, Lee S, Lim SY et al: Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. Respirology (Carlton, Vic) 2009, 14(2):260-263.

90. Kim SH, Ye YM, Hur GY, Lee HY, Jee YK, Lee SH, Holloway JW, Park HS: Effect of beta2- adrenergic receptor polymorphism in asthma control of patients receiving combination treatment. Yonsei medical journal 2009, 50(2):182-188.

91. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG: Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. American journal of respiratory and critical care medicine 2012, 186(10):975-981.

92. Lee WM: Drug-induced hepatotoxicity. The New England journal of medicine 2003, 349(5):474- 485.

93. Lemanske RF, Jr., Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB et al: Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. The New England journal of medicine 2010, 362(11):975-985.

94. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S et al: Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. Jama 2013, 309(21):2223-2231.

95. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, Palmer CN, Mukhopadhyay S: Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clinical science (London, England : 1979) 2013, 124(8):521-528.

96. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF: Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet (London, England) 2015, 385(9971):857-866.

97. Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ et al: Effect of roflumilast and inhaled corticosteroid/long-acting beta2- Agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

randomized clinical trial. American journal of respiratory and critical care medicine 2016, 194(5):559-567.

98. McCormack J CB, Calissi P: Dosage Adjustment in Renal Impairment. In: Therapeutics. Ottawa, ON: Canadian Pharmacists Association; 2018.

99. McGeachie MJ, Wu AC, Chang HH, Lima JJ, Peters SP, Tantisira KG: Predicting inhaled corticosteroid response in asthma with two associated SNPs. The pharmacogenomics journal 2013, 13(4):306-311.

100. McIvor RA: Chronic Obstructive Pulmonary Disease. In: Therapeutics. Edited by Gray J. Ottawa, ON: Canadian Pharmacists Association; 2017.

101. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ: Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993, 48(3):227-232.

102. Merck Canada Inc: Asmanex Twisthaler ( furoate DPI). In: CA Product Monograph. Kirkland, QC; 2018.

103. Merck Canada Inc: Zenhale (mometasone furoate / formoterol fumarate dihydrate ). In: CA Product Monograph. Kirkland, QC; 2018.

104. Merck Sharp & Dohme Corp: Asmanex HFA (mometasone furoate). In: US Product Monograph. Whitehouse Station, NJ; 2018.

105. Miravitlles M, Anzueto A: Antibiotic prophylaxis in COPD: Why, when, and for whom? Pulmonary pharmacology & therapeutics 2015, 32:119-123.

106. Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosio BG, Casanova C, Antonio Riesco J et al: Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Archivos de bronconeumologia 2017, 53(6):324-335.

107. Mougey EB, Chen C, Tantisira KG, Blake KV, Peters SP, Wise RA, Weiss ST, Lima JJ: Pharmacogenetics of asthma controller treatment. The pharmacogenomics journal 2013, 13(3):242-250.

108. National Institute for Health and Care Evidence: Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing [NICE Guideline NG114]. In.; 2018.

109. National Institute for Health and Care Evidence: Chronic obstructive pulmonary disease in over 16s: diagnosis and management [NICE guideline NG115]. 2018.

110. Novartis Pharmaceuticals Canada Inc: Foradil (formoterol). In: CA Product Monograph. Dorval, QC; 2013.

111. Novartis Pharmaceuticals Canada Inc: Onbrez Breezhaler (indacaterol maleate). In: CA Product Monograph. Dorval, QC; 2015.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

112. Novartis Pharmaceuticals Canada Inc: Seebri Breezhaler (glycopyrronium). In: CA Product Monograph. Dorval, QC; 2016.

113. Novartis Pharmaceuticals Canada Inc: Ultibro Breezhaler (indacaterol /glycopyrronium). In: CA Product Monograph. Dorval, QC; 2018.

114. Novartis Pharmaceuticals Corporation: Seebri Neohaler (glycopyrrolate). In: US Product Monograph. East Hanover, NJ; 2018.

115. Novartis Pharmaceuticals Corporation: Utibron Neohaler (indacaterol / glycopyrrolate). In: US Product Monograph. East Hanover, NJ; 2018.

116. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R et al: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Canadian respiratory journal 2007, 14 Suppl B:5b-32b.

117. O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, Balter M, Ford G, Gervais A, Lacasse Y et al: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Canadian respiratory journal 2008, 15 Suppl A:1A-8A.

118. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S: Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006, 61(11):940-944.

119. Pfizer Canada Inc: Zithromax (azithromycin). In: CA Product Monograph. Kirkland, QC; 2017.

120. Pfizer Canada Inc: Eryc (erythromycin delayed release). In: CA Product Monograph. Kirkland, QC; 2017.

121. Pfizer Laboratories Div Pfizer Inc: Zithromax (azithromycin). In: US Product Monograph. NY, NY; 2018.

122. Pomares X, Monton C, Espasa M, Casabon J, Monso E, Gallego M: Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. International journal of chronic obstructive pulmonary disease 2011, 6:449-456.

123. Purdue Pharma: Uniphyl (theophylline sr). In: CA Product Monograph. Pickering, ON; 2017.

124. Rabe KF: Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011, 163(1):53-67.

125. Rabe KF, Fabbri LM, Israel E, Kogler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF: Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. The Lancet Respiratory medicine 2014, 2(1):44-53.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

126. Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, Mazzini R, Goldstein R, Cendon S: Oral theophylline for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 2002(4):CD003902.

127. Ram FS, Jardin JR, Atallah A, Castro AA, Mazzini R, Goldstein R, Lacasse Y, Cendon S: Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respiratory medicine 2005, 99(2):135-144.

128. Rebordosa C, Kogevinas M, Guerra S, Castro-Giner F, Jarvis D, Cazzoletti L, Pin I, Siroux V, Wjst M, Anto JM et al: ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. The European respiratory journal 2011, 38(5):1029-1035.

129. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW: Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Archives of internal medicine 2010, 170(10):880-887.

130. Sanford JP, Gilbert DN, Sande MA: The Sanford guide to antimicrobial therapy. In., Pocket sized edn. Dallas, TX: Antimicrobial Therapy.

131. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA: Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. American journal of respiratory and critical care medicine 2008, 178(11):1139- 1147.

132. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respiratory research 2010, 11:10.

133. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. The European respiratory journal 2019, 53(5).

134. Slankard M, Michelis MA, Mansukhani M, McGoey B, Paige A, Andrews H, Lederer D, Canfield S, DiMango E: Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma. J Asthma 2016, 53(8):783-789.

135. Soleimani F, Fahimi F, Adimi Naghan P, Nadji SA, Morowati S, Naderi N, Masjedi MR: The effect of polymorphisms of beta2 adrenoceptors on response to long-acting beta2 agonists in Iranian asthmatic patients. Iran J Allergy Asthma Immunol 2013, 12(4):383-390.

136. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, Liggett SB, Gelfand EW, Rosenwasser LJ, Richter B et al: Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Human molecular genetics 2004, 13(13):1353-1359.

137. Teva Canada Limited: Theophylline SR. In: CA Product Monograph. Toronto, ON: Teva Canada Limited; 2011.

138. Teva Canada Limited: Ipratropium UDV. In: CA Product Monograph. Toronto, ON; 2013.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

139. Teva Respiratory LLC: QVAR Redihaler (beclomethasone dipropionate hfa). In: US Product Monograph. Frazer, PA; 2018.

140. Tsartsali L, Papadopoulos M, Lagona E, Papadimitriou A, Kanaka-Gantenbein C, Louizou E, Kastania A, Priftis KN, Chrousos G: Association of hypothalamic-pituitary-adrenal axis- related polymorphisms with stress in asthmatic children on inhaled corticosteroids. Neuroimmunomodulation 2012, 19(2):88-95.

141. Turner S, Francis B, Vijverberg S, Pino-Yanes M, Maitland-van der Zee AH, Basu K, Bignell L, Mukhopadhyay S, Tavendale R, Palmer C et al: Childhood asthma exacerbations and the Arg16 beta2-receptor polymorphism: A meta-analysis stratified by treatment. The Journal of allergy and clinical immunology 2016, 138(1):107-113 e105.

142. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM: Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory medicine 2014, 2(5):361-368.

143. Valeant Canada LP: QVAR (beclomethasone dipropionate) In: CA Product Monograph. Laval, QC; 2013.

144. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, Rabe KF, Fabbri LM, Investigators P-C: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. The New England journal of medicine 2011, 364(12):1093-1103.

145. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Jr., Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ et al: beta-Adrenergic receptor polymorphisms and response to salmeterol. American journal of respiratory and critical care medicine 2006, 173(5):519-526.

146. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L et al: Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet (London, England) 2009, 374(9703):1754-1764.

147. Wechsler ME, Yawn BP, Fuhlbrigge AL, Pace WD, Pencina MJ, Doros G, Kazani S, Raby BA, Lanzillotti J, Madison S et al: vs Long-Acting beta-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. Jama 2015, 314(16):1720-1730.

148. Wedzicha JA, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, Criner GJ, Papi A, Rabe KF, Rigau D et al: Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. The European respiratory journal 2017, 49(3).

149. Yancey SW, Klotsman M, Ortega HG, Edwards LD, Anderson WH: Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. Current medical research and opinion 2009, 25(4):1011-1018.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020

150. Yang IA, Clarke MS, Sim EH, Fong KM: Inhaled corticosteroids for stable chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 2012(7):CD002991.

151. Yelensky R, Li Y, Lewitzky S, Leroy E, Hurwitz C, Rodman D, Trifilieff A, Paulding CA: A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. The pharmacogenomics journal 2012, 12(6):484-488.

152. Zacarias EC, Castro AA, Cendon S: Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia 2007, 33(2):152-160.

153. Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S, Zheng J, Zhong N, Ran P: Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology (Carlton, Vic) 2006, 11(5):603-610.

154. Zuurhout MJ, Vijverberg SJ, Raaijmakers JA, Koenderman L, Postma DS, Koppelman GH, Maitland-van der Zee AH: Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort. Pharmacogenomics 2013, 14(16):1965-1971.

155. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K: Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001, 119(6):1661-1670.

GenXys Health Care Systems Inc. Commercial in Confidence February 2020